Aureon Prostate Px Test

New Topic Post Reply Printable Version
[ << Previous Thread | Next Thread >> ]

Klaats
New Member


Date Joined Sep 2009
Total Posts : 15
   Posted 9/25/2009 1:12 PM (GMT -6)   
Thanks so much for your responses to my first post on the forum. My knowledge base has increased exponentially. Guess it's best if I start a new thread with this separate question. Has anyone heard of Prostate PX test by Aureon (aureon.com)? I can't find it mentioned on this forum but it was recommended by my potential brachy Dr. It appears they give a more detailed analysis of the biopsy slides than Gleason scores. Sounds like a variation on what Dr. Epstein at Johns Hopkins has been recommending offering a more "complete" Gleason. If nothing else, sounds like yet another tool for determining future approach.
Age 56 - 6'0" 215lbs
Overall Heath Condition - Good
PSA - Feb '07-3.9, Feb '08-4.8, Feb '09-5.5, July '09-11.4, Sept. '09-6.1
Biopsy - 08/12/09 -> Gleason (3+3)6, Second analysis same biopsy (3+4)7
12 core. Cancer in 10% of one core.

Considering options


TeddyG
Regular Member


Date Joined Apr 2009
Total Posts : 133
   Posted 9/25/2009 10:39 PM (GMT -6)   
Klaats,
From my experience,research and discussions with docs, there is no bright line demarcation between Gleason 3 and 4 so that there could be variance between pathologists. My data is similar though numbers went in opposite direction. Being low volume is tricky because you don't know which way to turn. The question is did the biopsy find the needle in the haystack or the tip of the iceberg? You (and I) seem to be in that zone where one could wait and nothing will happen for years and years, but the science isn't there yet to tell us. Keep studying and asking questions as you step into the journey with the rest of the club members here. Once you feel that you know enough and make your decision on how to handle the situation, stick to it and don't look back.
Best wishes,
Ted
Background:
Age 55, two teens, very fit cyclist (avg 2000+ miles per year) and weight, diet, etc. consistent with good habits. Stressful job as attorney; very supporting wife who is helping me through every stage of this war.
Stats:
2006 PSA - 1.5
2007 PSA - 2.3
2008 PSA - 5.3 (18 mos.)
2009 Jan. 20 - Biopsy 12 samples
        Feb 3 Dx 2/12 samples positive, low volume  (5% and 7-10%)
Gleason 3+4, later downgraded by second opinion at Johns-Hopkins to 3+3, but "it's still PCa" as my Doc said.
Laproscopic surgery April 9,  University of KY Medical Center, Lexington, 3 days in hospital, catheter removal April 21.
Pathology: clear margins, no cancer in prostate: told that this is very rare and Doc has only seen it in 3 out of over 1400 cases; I rearched the concept of "vanishing cancer" and found a tumor classification of tP0 and asked Doc if it applied to me. He said that it was unlikely because if a pathologist had done a much more detailed analysis of the tissue, he would likely find more foci somewhere, and biopsy found "needle in the haystack as opposed to the tip of the iceberg"; Nevertheless, it is a blessing;
Regardless of the science, my family says "miracle."
Now working w/ post-surgery issues....
 


Tudpock18
Forum Moderator


Date Joined Sep 2008
Total Posts : 4274
   Posted 9/26/2009 9:02 AM (GMT -6)   

Dear Klaats:

I found the following, which you probably also have discovered by now, and include it for the education of our breathren on this site.  I had never heard of this test but it does sound promising.  Sounds like your doc is ahead of the curve and trying to get the best analysis possible before deciding on a definitive treatment plan.

If you go ahead with it, please let us know more...

Tudpock

Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, announced the introduction of Prostate Px®+, the first commercial test to predict prostate cancer progression and disease recurrence at the time of diagnosis. The announcement was made at the American Urological Association Annual Meeting, now underway at the Orange County Convention Center in Orlando (Booth# 505).

According to the National Prostate Cancer Coalition, 218,890 new cases of prostate cancer were diagnosed in 2007 and an estimated 27,050 American men died from the disease. It is estimated that by 2015, more than 300,000 men will be diagnosed annually. Existing guidelines from the American Urological Association assess patient risk based on information available at diagnosis: biopsy Gleason scores, prostate specific antigen (PSA) levels and clinical stage. However, as more men are diagnosed with lower-risk disease, these subjective parameters are becoming less useful.

Annual PSA screening has resulted in more men being caught earlier in the disease process than ever before. As a result, each year approximately 186,000 men with newly diagnosed prostate cancer will be assessed as low or intermediate risk, making it harder to determine which men have aggressive disease and which do not.

"Although the majority of prostate cancer cases are detected early and categorized as lower risk, there are a significant number of men within this segment whose tumors will grow aggressively, and jeopardize lives," said Dr. Vijay Aggarwal, President and Chief Executive Officer of Aureon Laboratories. "It is imperative that physicians have access to better tools that will assess disease severity and identify high-risk patients hidden within these lower-risk groups."

Prostate Px+ is based on the results of a large study utilizing data and samples from a cohort of 1,027 men assembled from the Mayo Clinic, Uppsala University, University of Connecticut and Duke University Medical Center. In validation, Aureon's predictive model identified twice as many high-risk events in low and intermediate risk patients than the best available method.

"Prostate Px+ is the first prognostic test to provide this critical information at diagnosis. This technology represents a new integrated approach known as systems pathology that combines molecular biomarkers, histological and clinical information with advanced mathematics," said Dr. Ricardo Mesa-Tejada, Vice President of Pathology and Medical Director of Aureon Laboratories. "At the time a man is diagnosed, Prostate Px+ will forecast disease progression after treatment, detect high-risk patients presenting as low risk and undetectable by other methods, reclassify intermediate-risk patients and help identify those with less aggressive disease.

"Newly diagnosed men with prostate cancer face difficult choices regarding treatment options, each of which can be curative but all with different side-effects that can negatively impact quality-of-life. The assessment of patient risk at diagnosis is critical to making the most appropriate treatment plans," added Dr. Mesa-Tejada. "Prostate Px+ will provide integrated and objective information to assist physicians and patients in making more educated and informed treatment decisions."


Age 62, Gleason 4 +3 = 7, T1C, PSA 4.2, 2 of 16 cores cancerous, 27cc
Brachytherapy December 9, 2008.  73 Iodine-125 seeds.  Procedure went great, catheter out before I went home, only minor discomfort.  Regular activities resumed, everything continues to function normally as of 9/1/09.  6 month PSA  1.4 and my docs are "delighted"!
New Topic Post Reply Printable Version
Forum Information
Currently it is Monday, September 24, 2018 4:18 AM (GMT -6)
There are a total of 3,005,994 posts in 329,291 threads.
View Active Threads


Who's Online
This forum has 161817 registered members. Please welcome our newest member, Butterfly_.
200 Guest(s), 2 Registered Member(s) are currently online.  Details
paul_t, Dimitri71